Two people follow the same calorie deficit. One loses weight steadily; the other barely moves after six weeks. Both have followed the plan. Neither is cheating. The difference isn't willpower — it's how their metabolisms are wired. And a meaningful part of that wiring is genetic.
Weight management is one of the most genetically complex traits in nutrition. Dozens of genes play a role. But three in particular — FTO, ADRB2 and PPARG — are among the most studied and the most clinically relevant. Together they explain a large portion of why two people respond so differently to identical interventions.
FTO: the strongest known weight-related gene
FTO stands for "fat mass and obesity associated" — an unglamorous name that accurately reflects what early research found. The key variant is rs9939609. People carrying the A allele (vs. the T allele) have a consistently higher risk of increased BMI and obesity in large-scale genetic studies. Two copies of the A allele (AA genotype) carry a significantly higher risk compared to TT carriers.
But FTO's mechanism isn't simply about storing more fat. Research has converged on its role in the brain, specifically in appetite regulation and satiety signalling. FTO appears to affect levels of ghrelin (the hunger hormone) and the speed at which the brain registers fullness. AA carriers tend to feel less satisfied after a meal of the same caloric content and become hungry again sooner.
This is a clinically important distinction. FTO's primary effect isn't metabolic rate — it's appetite. Two people might burn similar calories but one feels full after 400kcal while the other is still hungry. Strategies focused only on macros miss this entirely.
Crucially, FTO's effect on weight is significantly modified by physical activity. Studies consistently show that the genetic risk from the A allele is substantially attenuated — in some cases eliminated — in physically active individuals. This is one of the clearest gene-environment interactions in nutrition science: FTO doesn't determine your weight, but it determines how much your activity level matters.
ADRB2: how efficiently you mobilise stored fat
ADRB2 encodes the beta-2 adrenergic receptor, which sits on fat cells and responds to adrenaline and exercise signals. When you exercise or restrict calories, adrenaline rises and signals fat cells to release stored fat for energy — a process called lipolysis. The ADRB2 receptor is the lock that adrenaline turns.
Two variants matter most: Arg16Gly (rs1042713) and Gln27Glu (rs1042714). Their effects interact, making combined genotype the relevant measure rather than either variant alone.
The combination that most impacts fat loss is the Gly16/Glu27 haplotype. Research shows carriers of this combination have a blunted lipolysis response — their fat cells are slower to release stored fat in response to exercise and calorie restriction. Same workout, slower fat mobilisation. This is why some people plateau despite consistent effort: their fat cells are relatively resistant to the normal signals to release energy.
For ADRB2 risk profiles, the evidence points toward specific strategies: higher exercise frequency (more frequent adrenaline pulses rather than fewer intense sessions), and nutritional support for fat mobilisation — particularly L-carnitine, which facilitates fatty acid transport into mitochondria for burning.
PPARG: where fat is stored and how insulin-sensitive you are
PPARG (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that acts as a master regulator of fat cell formation and function. It also plays a central role in insulin sensitivity — the efficiency with which cells respond to insulin and take up glucose.
The Pro12Ala variant (rs1801282) is the most studied. The Pro12 (common) variant is associated with slightly higher fat storage tendency and modestly reduced insulin sensitivity compared to the Ala12 variant, which counter-intuitively appears modestly protective against insulin resistance and type 2 diabetes.
PPARG also influences where fat is preferentially deposited — visceral (around organs, metabolically active and risky) versus subcutaneous (under the skin, metabolically less dangerous). Variants that push toward more visceral fat deposition matter more for cardiovascular and metabolic health than total weight.
From a nutritional angle, PPARG function is significantly modified by omega-3 fatty acids — EPA and DHA directly bind to the PPARG receptor and modulate its activity. This is one mechanism behind omega-3's insulin-sensitising effects, and it's more pronounced in carriers of specific PPARG variants.
These genes interact — and that's the point
The real value of looking at FTO, ADRB2 and PPARG together is that they shape different parts of the same problem. FTO affects how hungry you get. ADRB2 affects how efficiently you burn stored fat. PPARG affects where fat is stored and how insulin-sensitive you are. A generic diet plan that ignores these signals can be perfectly rational and still systematically wrong for the person following it.
Someone who is FTO risk/AA, ADRB2 Gly16/Glu27, and PPARG Pro12 has a very different nutritional profile than someone who is TT, Arg16/Gln27, and Ala12 — even if both have the same BMI and the same stated goal. The same calorie target, the same macros, the same supplement — but very different optimal strategies.
What the nutritional interventions look like
Across these three genes, the nutritional implications that come up most consistently are:
- Protein adequacy — higher protein increases satiety signalling and is particularly important for FTO risk profiles where hunger regulation is impaired
- Omega-3 fatty acids (EPA + DHA) — relevant for PPARG function, insulin sensitivity, and anti-inflammatory support during fat mobilisation
- L-carnitine — facilitates fatty acid transport into mitochondria; most relevant for ADRB2 risk profiles with blunted lipolysis
- Chromium — supports insulin signalling and glucose uptake; relevant for PPARG-associated insulin sensitivity concerns
- Magnesium — involved in insulin receptor signalling and glucose metabolism; frequently deficient in people with metabolic challenges
None of this replaces a calorie deficit if weight loss is the goal. But which supporting nutrients you actually need, at what dose, depends on which genetic levers are pulling against you.
What MyGNLab uses it for
FTO, ADRB2 and PPARG are all included in the DNA analysis. Your report explains which weight-related variants you carry and what they mean in practical terms for your metabolism. Your supplement formula addresses the specific nutritional gaps and support pathways that your genotype points toward — whether that's appetite-satiety support, fat mobilisation, insulin sensitivity, or all three.
Tired of approaches that don't account for how you're actually built?
One saliva test reads FTO, ADRB2, PPARG and 54 other markers, then builds a supplement formula matched to your metabolism — not the average metabolism.
See pricing